BioPharmSignal logoBioPharmSignal

Biotech News

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio (TIL)Instil BioEarnings

First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumors DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a

Related news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

Instil Bio

Therapeutics Acquisition Strategy Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutics. It is evaluating acquisitions, in-licensing transactions, and related opportunities that could provide access to new drug candidates. Portfolio Rebuilding Following the wind-down of prior internal...

Recent company news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-05-15 11:00 EST

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-03-27 11:00 EST

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TILInstil Bio2026-01-06 12:00 EST

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

TILInstil Bio2025-11-13 12:00 EST

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
7.58 USD
Market cap
55M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States